PHS
ORKA

PFM Health Sciences’s Oruka Therapeutics ORKA Stock Holding History

PFM Health Sciences’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1M Sell
158,825
-15,227
-9% -$1.01M 1.3% 27
2026
Q1 		$8.54M Buy
+174,052
New +$6.05M 0.78% 43

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PFM Health Sciences's ORKA Position: Q2 2026 in Review

PFM Health Sciences reduced its Oruka Therapeutics (ORKA) stake by 8.7% in Q2 2026, selling an estimated $1.01M and leaving 158,825 shares worth $15.1M. The position accounts for 1.3% of the portfolio, ranked #27.

PFM Health Sciences first reported a position in ORKA in Q1 2026 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • PFM Health Sciences held 158,825 shares of Oruka Therapeutics worth $15.1M as of Q2 2026.
  • PFM Health Sciences sold 15,227 Oruka Therapeutics shares in Q2 2026, an estimated $1.01M.
  • Oruka Therapeutics made up 1.3% of PFM Health Sciences's portfolio in Q2 2026, its #27 holding.
  • PFM Health Sciences first reported a position in Oruka Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.